Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

RICHMOND, Calif., November 12, 2024 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial ...

primarily due to their Genentech agreement, leading to a net income of $10.7 million compared to a loss in the previous year. Strategic developments include the submission of an IND application for a ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...

"I am thrilled to further strengthen and enrich Ocular's senior leadership team with the appointment of Namrata as Chief ...

At the heart of the alliance is the ‘lab-in-the-loop’ concept pioneered at Genentech’s Prescient Design accelerator unit. In a nutshell, that involves drawing on the company’s rich source ...

“Onco360 is grateful for the opportunity to partner with the team at Genentech and become a specialty pharmacy provider for Itovebi ™ ,” said Benito Fernandez. “We are proud to add another treatment ...

Specifically, I will discuss the acquisition of Dermavant Sciences Ltd., a Roivant Sciences Ltd. (ROIV) company, with a focus ...